Worth Venture Partners’s Cyclo Therapeutics, Inc. Warrant CYTHW Stock Holding History

Worth Venture Partners’s Portfolio CYTHW Stock Details CYTHW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-70,570	Closed	-$36.7K	–	217
2022 Q4	$36.7K	Sell	70,570 -3,166	-4%	-$1.87K	0.02%	138
2022 Q3	$26K	Sell	73,736 -500	-0.7%	-$259	0.02%	153
2022 Q2	$54K	Sell	74,236 -500	-0.7%	-$489	0.03%	126
2022 Q1	$99K	Hold	74,736	–	–	0.05%	121
2021 Q4	$149K	Sell	74,736 -13,954	-16%	-$33.6K	0.07%	108
2021 Q3	$223K	Hold	88,690	–	–	0.1%	104
2021 Q2	$458K	Hold	88,690	–	–	0.17%	88
2021 Q1	$333K	Hold	88,690	–	–	0.16%	84
2020 Q4	$96K	Buy	+88,690	New	+$109K	0.08%	86

Other funds holding CYTHW

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Worth Venture Partners's CYTHW Position: Q1 2023 in Review

Worth Venture Partners sold out of Cyclo Therapeutics, Inc. Warrant (CYTHW) in Q1 2023, closing a stake of 70,570 shares — an estimated $36.7K sold.

Worth Venture Partners first reported a position in CYTHW in Q4 2020 and held it in 9 quarters. The position peaked at $458K in Q2 2021. 1 fund tracked by Wall St. Rank holds CYTHW as of Q1 2023.

Worth Venture Partners reported no remaining Cyclo Therapeutics, Inc. Warrant position as of Q1 2023 after selling out during the quarter.
Worth Venture Partners sold 70,570 Cyclo Therapeutics, Inc. Warrant shares in Q1 2023, an estimated $36.7K.
Worth Venture Partners first reported a position in Cyclo Therapeutics, Inc. Warrant in Q4 2020 and held it in 9 quarters.
Worth Venture Partners's Cyclo Therapeutics, Inc. Warrant position peaked at $458K in Q2 2021.
1 fund tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Warrant as of Q1 2023.

Based on Worth Venture Partners's 13F filing for Q1 2023, filed 15 May 2023.